Kenneth L. Davis

Last updated
Kenneth L. Davis, MD
Kenneth-davis.jpg
Nationality American
Education Mount Sinai School of Medicine, Stanford University School of Medicine, Stanford University Hospital
Occupation(s)Executive vice chairperson of the board of trustees at the Mount Sinai Health System
Known for Psychiatry
Medical career
Field Psychiatry, Alzheimer's disease, schizophrenia
Institutions Mount Sinai Health System
Notable worksAlzheimer's Disease Assessment Scale
Awards George H. W. Bush Lifetime of Leadership Award
Website Kenneth L. Davis, MD

Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City, [1] [2] and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease. [3] [4] His research led to four of the first five FDA-approved drugs for Alzheimer's. [5]

Contents

Biography

Education

Davis graduated magna cum laude from Yale College in 1969 and was the valedictorian of Mount Sinai School of Medicine's second graduating class in 1973 with his M.D., where he received the Harold Elster Memorial Award for highest academic achievement. [6] Supplementary graduate medical education was later completed at Stanford University.

Career

In 1979, Davis was made chief of psychiatry at Bronx Veteran's Affairs Medical Center, where he became the first director of its Schizophrenia Biological Research Center. From 1987 until 2003, he was chairman of psychiatry at Mount Sinai School of Medicine.

In 2003, Davis was appointed dean of Mount Sinai School of Medicine and held that position until 2007, when he was succeeded by Dennis S. Charney, M.D. Davis was also appointed as the president and CEO of Mount Sinai Medical Center in 2003 – a position he held until 2024. In 2015, Davis had gross compensation from the Icahn School of Medicine at Mount Sinai of $4,147,755.[ relevant? ] He is the director of the Mount Sinai Silvio Conte Neuroscience Center, trustee of the New York Academy of Medicine, trustee of the Aspen Institute, [7] [8] and chair of the New York Academy of Medicine Deans Council. In addition, he has served as chairman of the board of governors for the Greater New York Hospital Association.

In September 2013, when Mount Sinai Medical Center merged with Continuum Health Partners, Davis became the president and CEO of the Mount Sinai Health System. In 2017, his annual salary was $12 million. [9] [ relevant? ]

Davis has weighed in on the intersection of health and public policy, arguing that the National Institutes of Health should receive more funds to fight disease and calling drug prices 'outrageous' and a fair trade issue. [10] [11]

Awards and recognition

Research

Alzheimer's research

Davis participated in breakthrough proof-of-concept studies and clinical trials of cholinesterase inhibitors. These trials (the first multicenter ones for cholinesterase inhibitors) established efficacy and ultimately led to the first four of the five FDA-approved compounds for treating the symptoms of Alzheimer's: tacrine, rivastigmine, galantamine, donepezil and memantine [15] [5]

In 1978, Davis, together with Richard Mohs, conducted the first well-controlled study of a drug that was shown able to improve the storage and retrieval functions of long-term memory in humans. [16]

In 1987, Davis participated in the first study providing strong evidence that Alzheimer's risk is inherited. [17]

His Alzheimer Disease Assessment Scale (ADAS) is one of two primary cognitive measures used for all Food and Drug Administration (FDA) Altzheimer's-related clinical drug trials in the US. [18]

While at Mount Sinai Hospital, Davis and his associates have been at the forefront in the delineation of the role of amyloid in Alzheimer's disease, [16] and were among the first to report the cloning and chromosomal location of the amyloid precursor protein, regarded as one of the most important discoveries in Alzheimer's research in the previous 15 years. [19]

Schizophrenia research

Davis's work on schizophrenia has shown that oligodendroglia cells and myelin play roles in the disease's pathophysiology [20] and that dopamine – long thought to be merely hyperactive in a schizophrenic brain – is actually hypoactive in different regions. [21]

His paper, "Dopamine in schizophrenia—a review and reconceptualization" (American Journal of Psychiatry, 148-11: 1474–86, November 1991) is the third most-cited paper on schizophrenia research in its decade. [22]

While studies have shown that individuals born in winter months are disproportionately likely to develop schizophrenia, Davis participated in a 2006 study that demonstrated that this disproportionality also exists in tropical regions, ruling out cold weather as the cause. [23]

Publications

Editor and editorial roles

Books

Articles

According to ResearchGate, Davis' peer-reviewed articles have been cited 28,265 times. He is credited with more than 575 articles. [5] Select list:

Related Research Articles

Catechol-<i>O</i>-methyltransferase Class of enzymes

Catechol-O-methyltransferase is one of several enzymes that degrade catecholamines, catecholestrogens, and various drugs and substances having a catechol structure. In humans, catechol-O-methyltransferase protein is encoded by the COMT gene. Two isoforms of COMT are produced: the soluble short form (S-COMT) and the membrane bound long form (MB-COMT). As the regulation of catecholamines is impaired in a number of medical conditions, several pharmaceutical drugs target COMT to alter its activity and therefore the availability of catecholamines. COMT was first discovered by the biochemist Julius Axelrod in 1957.

<span class="mw-page-title-main">Muscarinic agonist</span> Activating agent of the muscarinic acetylcholine receptor

A muscarinic agonist is an agent that activates the activity of the muscarinic acetylcholine receptor. The muscarinic receptor has different subtypes, labelled M1-M5, allowing for further differentiation.

Geriatric psychiatry, also known as geropsychiatry, psychogeriatrics or psychiatry of old age, is a branch of medicine and a subspecialty of psychiatry dealing with the study, prevention, and treatment of neurodegenerative, cognitive impairment, and mental disorders in people of old age. Geriatric psychiatry as a subspecialty has significant overlap with the specialties of geriatric medicine, behavioural neurology, neuropsychiatry, neurology, and general psychiatry. Geriatric psychiatry has become an official subspecialty of psychiatry with a defined curriculum of study and core competencies.

<span class="mw-page-title-main">Dennis S. Charney</span> American medical researcher

Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

<span class="mw-page-title-main">Alzheimer's disease</span> Progressive neurodegenerative disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.

<span class="mw-page-title-main">Jeffrey Lieberman</span> American psychiatrist (born 1948)

Jeffrey Alan Lieberman is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience (biology) and pharmacological treatment. He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing pharmacotherapies for schizophrenia. He was president of the American Psychiatric Association from May 2013 to May 2014.

Samuel E. Gandy, is a neurologist, cell biologist, Alzheimer's disease (AD) researcher and expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Alzheimer's. His team discovered the first drugs that could lower the formation of amyloid.

Sophia Frangou is a professor of psychiatry at the Icahn School of Medicine at Mount Sinai where she heads the Psychosis Research Program. She is a Fellow of the Royal College of Psychiatrists and vice-chair of the RCPsych Panamerican Division. She is a Fellow of the European Psychiatric Association (EPA) and of the American Psychiatric Association (APA). She served as vice-president for Research of the International Society for Bipolar Disorders from 2010 to 2014. She has also served on the Council of the British Association for Psychopharmacology. She is founding member of the EPA NeuroImaging section and founding chair of the Brain Imaging Network of the European College of Neuropsychopharmacology. She is one of the two Editors of European Psychiatry, the official Journal of the European Psychiatric Association.

William Koopmans Summers is an independent neuroscientist and was the inventor of Tacrine (Cognex) as a treatment for Alzheimer's disease {US Patent No. 4,816,456}. Tacrine was the first FDA approved anti-dementia drug. Today there are five FDA approved anti-dementia drugs.

Dilip V. Jeste is an American geriatric neuropsychiatrist, who specializes in successful aging as well as schizophrenia and other psychotic disorders in older adults. He was senior associate dean for healthy aging and senior care, distinguished professor of psychiatry and neurosciences, Estelle and Edgar Levi Memorial Chair in Aging, director of the Sam and Rose Stein Institute for Research on Aging, and co-director of the IBM-UCSD Artificial Intelligence Center for Healthy Living at the University of California, San Diego School of Medicine. after serving for 36 years, he retired from UC San Diego on July 1, 2022.

<span class="mw-page-title-main">Moussa B. H. Youdim</span>

Moussa B. H. Youdim is an internationally renowned Israeli neuroscientist specializing in neurochemistry and neuropharmacology. He is the discoverer of both monoamine oxidase (MAO) B inhibitors l-deprenyl (Selegiline) and rasagiline (Azilect) as anti-Parkinson drugs which possess neuroprotective activities. He is currently professor emeritus at Technion - Faculty of Medicine and President of Youdim Pharmaceuticals.

Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">Giulio Maria Pasinetti</span>

Giulio Maria Pasinetti is the Program Director of the Center on Molecular Integrative Neuroresilience and is the Saunders Family Chair in Neurology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Pasinetti is a Professor of Neurology, Psychiatry, Neuroscience, and Geriatrics and Palliative Medicine at ISMMS.

Steven M. Paul is an American neuroscientist and pharmaceutical executive. As of 2021, Paul serves as the CEO, president and chairman of Karuna Therapeutics.

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion. The most common side effects of lecanemab include headache, infusion-related reactions and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid.

Joseph Thomas Coyle Jr. is an American psychiatrist and neuroscientist. He is known for his work on the neurobiology of mental illness, more specifically on schizophrenia. He is currently the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard Medical School. He was President of the Society of Neuroscience from 1991–1992, and also the president of the American College of Neuropsychopharmacology in 2001. He is a member of the Institute of Medicine.

René Sylvain Kahn is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017. He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.

<span class="mw-page-title-main">Bita Moghaddam</span> Iranian-American neuroscientist

Bita Moghaddam is an Iranian-American neuroscientist and author. She is currently the Ruth Matarazzo Professor of Behavioral Neuroscience at Oregon Health & Science University. Moghaddam investigates the neuronal processes underlying emotion and cognition as a first step to designing strategies to treat and prevent brain illnesses.

Rachelle Smith Doody is an American neurologist and neuroscientist. She is known for her work on late stage development of drugs for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other neurodegenerative disorders.

Alzheimer's disease (AD) in African Americans is becoming a rising topic of interest in AD care, support, and scientific research, as African Americans are disproportionately affected by AD. Recent research on AD has shown that there are clear disparities in the disease among racial groups, with higher prevalence and incidence in African Americans than the overall average. Pathologies for Alzheimer’s also seem to manifest differently in African Americans, including with neuroinflammation markers, cognitive decline, and biomarkers. Although there are genetic risk factors for Alzheimer’s, these account for few cases in all racial groups.

References

  1. ↑ "Mount Sinai Boards of Trustees Announce Updated Leadership Structure | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2021-11-09.
  2. ↑ Neber, Jaqueline (November 21, 2023). "Mount Sinai Health System names Dr. Brendan Carr as next CEO". Craine's New York Business. Retrieved January 14, 2023.
  3. ↑ A new rating scale for Alzheimer's disease, American Journal of Psychiatry
  4. ↑ "Mt Sinai Hospital -- IRS Form 990 2017". Pro Publica Non Profit Explorer. 9 May 2013. Retrieved July 1, 2019.
  5. 1 2 3 "How Dr. Kenneth Davis Turned the Mount Sinai Health System Around". 1A. Retrieved 2022-04-27.
  6. ↑ New York Times
  7. ↑ "Board of Trustees – The Aspen Institute". The Aspen Institute. Retrieved 2017-05-16.
  8. ↑ Institute, The Aspen. "Six Leaders Elected to Aspen Institute Board of Trustees". www.prnewswire.com. Retrieved 2017-05-16.
  9. ↑ "Mt Sinai Hospital IRS Form 990, Return of Organization Exempt From Income Tax (2017)". Pro Publica Nonprofit Explorer. July 1, 2019. Retrieved July 1, 2019.
  10. ↑ Bachai, Sabrina (2017-12-05). "Congress should massively ramp up funding for the NIH". TheHill. Retrieved 2018-06-06.
  11. ↑ Fox, Michelle (2018-05-17). "'Outrageous' drug prices are a fair trade issue: Mt. Sinai CEO". CNBC. Retrieved 2018-06-06.
  12. ↑ "Archived copy". Archived from the original on 2015-03-09. Retrieved 2015-04-06.{{cite web}}: CS1 maint: archived copy as title (link)
  13. ↑ "Yale Bulldogs: Yale Athletic Department Hosts Blue Leadership Ball" . Retrieved December 31, 2009.
  14. ↑ "100 Most Influential People in Healthcare - Dr. Kenneth Davis". Modern Healthcare. 2021-12-09. Retrieved 2022-04-27.
  15. ↑ U.S. Food and Drug Administration
  16. 1 2 Science Magazine
  17. ↑ Strong New Evidence Found of Inherited Alzheimer Risk, New York Times
  18. ↑ "Alzheimer Disease Assessment Scale - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2022-04-27.
  19. ↑ The Journal of the American Medical Association
  20. ↑ Myelin and oligodendrocyte abnormalities in schizophrenia, Cambridge Journals
  21. ↑ Schizophrenia, Bipolar May Share Cause, WebMD.com
  22. ↑ Science Watch
  23. ↑ Seasonality effects on schizophrenic births in multiplex families in a tropical island
  24. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
  25. ↑ Ripke, Stephan; Neale, Benjamin M; Corvin, Aiden; Walters, James TR; Farh, Kai-How; Holmans, Peter A; Lee, Phil; Bulik-Sullivan, Brendan; Collier, David A; Huang, Hailiang; Pers, Tune H (2014-07-24). "Biological Insights From 108 Schizophrenia-Associated Genetic Loci". Nature. 511 (7510): 421–427. Bibcode:2014Natur.511..421S. doi:10.1038/nature13595. ISSN   0028-0836. PMC   4112379 . PMID   25056061.
  26. 1 2 3 4 5 6 7 "Google Scholar". scholar.google.com. Retrieved 2022-04-27.
  27. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
  28. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
  29. ↑ Näslund, Jan; Haroutunian, Vahram; Mohs, Richard; Davis, Kenneth L.; Davies, Peter; Greengard, Paul; Buxbaum, Joseph D. (2000-03-22). "Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline". JAMA. 283 (12): 1571–1577. doi:10.1001/jama.283.12.1571. ISSN   0098-7484. PMID   10735393.
  30. ↑ Coccaro, Emil F.; Siever, Larry J.; Klar, Howard M.; Maurer, Gail; Cochrane, Karen; Cooper, Thomas B.; Mohs, Richard C.; Davis, Kenneth L. (1989-07-01). "Serotonergic Studies in Patients With Affective and Personality Disorders: Correlates With Suicidal and Impulsive Aggressive Behavior". Archives of General Psychiatry. 46 (7): 587–599. doi:10.1001/archpsyc.1989.01810070013002. ISSN   0003-990X. PMID   2735812.
  31. ↑ Hakak, Yaron; Walker, John R.; Li, Cheng; Wong, Wing Hung; Davis, Kenneth L.; Buxbaum, Joseph D.; Haroutunian, Vahram; Fienberg, Allen A. (2001-04-10). "Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia". Proceedings of the National Academy of Sciences. 98 (8): 4746–4751. Bibcode:2001PNAS...98.4746H. doi: 10.1073/pnas.081071198 . ISSN   0027-8424. PMC   31905 . PMID   11296301.
  32. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.